Clear Data for Nivolumab & Ipilimumab | In the Frontline for Intermediate & Poor-Risk Patients
Aly-Khan A. Lalani, MD, FRCPC Juravinski Cancer Centre, explains Clear Data for Nivolumab & Ipilimumab | In the Frontline for Intermediate & Poor-Risk Patients at ASCO 2018
Author: Annual-Meeting
Added: 06/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts
New Combination Strategy for Metastatic RCC | Checkmate-214 Data for Nivolumab & Ipilimumab
Aly-Khan A. Lalani, MD, FRCPC Juravinski Cancer Centre, explains New Combination Strategy for Metastatic RCC | Checkmate-214 Data for Nivolumab & Ipilimumab at ASCO 2018
Author: Annual-Meeting
Added: 06/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts
Update on Checkmate-214 Study | Approval of Nivolumab & Ipilimumab Combination
Saby George, MD, FACP, Roswell Park Cancer Institute, explains Update on Checkmate-214 Study | Approval of Nivolumab & Ipilimumab Combination at ASCO 2018
Author: Annual-Meeting
Added: 06/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 20, 2018 Category: Cancer & Oncology Source Type: podcasts
Vaccine Immunotherapy with Cytoxan & Interferon | Eventually add Ipilimumab or Pembrolizumab
Saveri Bhattacharya, DO, Thomas Jefferson University, talks about Vaccine Immunotherapy with Cytoxan & Interferon | Eventually add Ipilimumab or Pembrolizumab at ASCO 2018
Author: Annual-Meeting
Added: 06/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 9, 2018 Category: Cancer & Oncology Source Type: podcasts
ECOG-ACRIN EA6134 Ipilimumab + Nivolumab vs. Dabrafenib + Trametinib
Ahmad Tarhini, MD, PhD, Cleveland Clinic Main Campus, talks about ECOG-ACRIN EA6134 Ipilimumab + Nivolumab vs. Dabrafenib + Trametinib at ASCO 2018
Author: Annual-Meeting
Added: 06/05/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Are Tumor Mutation Burden and Nivolumab/Ipilimumab Ready for Clinical Use? Insights from CheckMate 227 (BMIC-035)
Dr. Jack West reviews the CheckMate 227 trial, summarizing highlights from efficacy & side effects of nivolumab/ipilimumab (nivo/ipi) compared to standard doublet chemotherapy in patients with adv...
Author: BeaconMedIC
Added: 05/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 11, 2018 Category: Cancer & Oncology Source Type: podcasts
Nivolumab/Ipilimumab vs. Chemo in High TMB Advanced NSCLC: Key Results from CheckMate 227 (BMIC-034)
Dr. Jack West reviews the CheckMate 227 trial, summarizing highlights from efficacy & side effects of nivolumab/ipilimumab (nivo/ipi) compared to standard doublet chemotherapy in patients with adv...
Author: BeaconMedIC
Added: 05/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 10, 2018 Category: Cancer & Oncology Source Type: podcasts
Nivolumab/Ipilimumab vs. Chemo in High TMB Advanced NSCLC: Key Results from CheckMate 227
Dr. Jack West reviews the CheckMate 227 trial, summarizing highlights from efficacy & side effects of nivolumab/ipilimumab (nivo/ipi) compared to standard doublet chemotherapy in patients with adv...
Author: BeaconMedIC
Added: 05/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 10, 2018 Category: Cancer & Oncology Source Type: podcasts
Lack of Randomized Data to Compare Drugs Nivolumab + Ipilimumab showed high response rate Randomized Data to Compare 1 Drug to Another
Marwan Fakih, MD, explains Lack of Randomized Data to Compare Drugs Nivolumab + Ipilimumab showed high response rate Randomized Data to Compare 1 Drug to Another at the 2018 Oncology Summit in Huntin...
Author: moasc
Added: 03/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 9, 2018 Category: Cancer & Oncology Source Type: podcasts
Nivolumab + Ipilimumab Front Line bevacizumab atezolizumab
Sumanta (Monty) Kumar Pal, M.D. Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research Co-director, Kidney Cancer Program, Medical Oncologist, shares thoughts on Nivoluma...
Author: moasc
Added: 03/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Lower-Dose Combo Immunotherapy Promising for Advanced Melanoma
Dr Jeffrey S. Weber reviews data from an open-label phase 1/2 trial assessing the efficacy and safety of combination pembrolizumab and reduced-dose ipilimumab in patients with advanced melanoma. (Source: Medscape Oncology)
Source: Medscape Oncology - February 22, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
Checkmate 42 Nivolumab & Ipilimumab 55Response Rate in MSI High
Cathy Eng, MD, FACP GASTROINTESTINAL MEDICAL ONCOLOGY - MD Anderson discusses the trial Checkmate 42 Nivolumab & Ipilimumab and how it has shown a 55% Response Rate in MSI High patients. Recorded at A...
Author: Gastrointestinal-Cancer-Meeting
Added: 01/25/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 26, 2018 Category: Cancer & Oncology Source Type: podcasts
Checkmate 142 Nivolumab & amp; Ipilimumab 55Response Rate in MSI High
Cathy Eng, MD, FACP GASTROINTESTINAL MEDICAL ONCOLOGY - MD Anderson discusses the trial Checkmate 142 Nivolumab & Ipilimumab and how it has shown a 55% Response Rate in MSI High patients. Recorded...
Author: Gastrointestinal-Cancer-Meeting
Added: 01/25/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 26, 2018 Category: Cancer & Oncology Source Type: podcasts
Mesothelioma New Salvage Guidelines Pembrolizumab & Ipilimumab Nivolumab
Anne S. Tsao, MD of MD Anderson Cancer Center discusses the mesothelioma new salvage guidelines pembrolizumab & ipilimumab nivolumab from the 22nd Annual Perspectives in Thoracic Oncology in New York ...
Author: thoraciconcology
Added: 12/29/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 29, 2017 Category: Cancer & Oncology Source Type: podcasts
Discussion of Correlatives Associated with Presurgical Nivolumab + - Bevacizumab or Ipilimumab Trial in mccRCC
Discussion of Correlatives Associated with Presurgical Nivolumab + - Bevacizumab or Ipilimumab Trial i...
Author: kidneycancer
Added: 11/07/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 7, 2017 Category: Cancer & Oncology Source Type: podcasts
